You are here

Our science / Clinical Trials / Find a Trial / NCT00460408

Ocular Safety Of Patients Receiving Macugen For Neovascular Age Related Macular Degeneration

Back to Search Print Save as PDF Bookmark Trial

NCT00460408

Last updated on April 10, 2018
Back to Search Print Save as PDF Bookmark Trial

FOR MORE INFORMATION
Study Location
Pfizer Investigational Site
Bruxelles, , 1200 Belgium
See other locations
Contact
1-800-718-1021
[email protected]
Related Links
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Macular Degeneration
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18+ years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Neovascular AMD patients who are eligible for Macugen therapy based on the approved
label

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Active or suspected ocular or periocular infection. Known hypersensitivity to the
active substance or any of its excipients.

NCT00460408
Pfizer
Completed
Ocular Safety Of Patients Receiving Macugen For Neovascular Age Related Macular Degeneration

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your zip code, city, or country to find studies near you.
Advanced Search

Similar Trials

Age Related Macular Degeneration
Retinal Pigment Epithelium Safety Study For Patients In B4711001
NCT03102138
All Genders
60+
Years
London,
Neovascular Age-related Macular Degeneration
Efficacy, Safety, Tolerability of Pegaptanib Sodium (Macugen) in Filipino Patients With Neovascular Age Related Macular Degeneration.
NCT00820742
All Genders
Choroidal Neovascularization (CNV), Age-related Macular Degeneration (AMD), Early Markers
A Study Of Early Markers Of Choroidal Neovascularization
NCT00902785
All Genders
50+
Years
Multiple Sites
Vascular Endothelial Growth Factor, Macular Degeneration
Macugen Observational Study
NCT00735943
All Genders
18+
Years
Multiple Sites
Ocular Safety Of Patients Receiving Macugen For Neovascular Age Related Macular Degeneration
European Epidemiologic COHORT Study: A Prospective Epidemiologic COHORT Study Of Ocular Safety In Patients Receiving Macugen Injections For Neovascular Age-Related Macular Degeneration (AMD) In Europe
The study will provide additional safety data for specific safety events in persons receiving intravitreal injections. The Committee for Medicinal Products for Human Use (CHMP) is interested in obtaining additional safety information when Macugen is used in real world settings by practitioners in Europe treating patients with neovascular (wet) age-related macular degeneration (AMD). The study will provide information about physician practice patterns and characteristics of patients treated with Macugen.
No comparator Patients with age-related macular degeneration
Observational
Time Perspective: Prospective
Not Provided
Not Provided
Non-Probability Sample
Patients with age-related macular degeneration
Macular Degeneration
Drug: Macugen
Intravitreal injection of Macugen 0.3mg/90ul every 6 weeks.
Observational study, no comparator
Observational study of patients with AMD treated with Macugen, no comparator
Intervention: Drug: Macugen
Not Provided


*   Includes publications given by the data provider as well as publications
identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
501
February 2012
February 2012   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Neovascular AMD patients who are eligible for Macugen therapy based on the approved label

Exclusion Criteria:

  • Active or suspected ocular or periocular infection. Known hypersensitivity to the active substance or any of its excipients.
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
Belgium,   Cyprus,   Czech Republic,   Denmark,   France,   Germany,   Greece,   Ireland,   Italy,   Poland,   Slovakia,   Spain,   Sweden
 
 
NCT00460408
A5751019
No
Not Provided
Not Provided
Pfizer
Pfizer
Not Provided
Study Director: Pfizer CT.gov Call Center Pfizer
Pfizer
November 2012

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting thte study website. To get updates and notications about this trail, sign up using the form below.

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]



Call Now